Simeon George - Dec 16, 2022 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Signature
/s/ Sasha Keough, attorney-in-fact
Stock symbol
DSGN
Transactions as of
Dec 16, 2022
Transactions value $
$7,574,078
Form type
4
Date filed
12/20/2022, 05:45 PM
Previous filing
Aug 17, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DSGN Common Stock Purchase $4.14M +500K +8.89% $8.28 6.13M Dec 16, 2022 See Note 2 F1, F2
transaction DSGN Common Stock Purchase $3.11M +360K +5.88% $8.63 6.49M Dec 19, 2022 See Note 2 F2, F3
transaction DSGN Common Stock Purchase $325K +40K +0.62% $8.14 6.53M Dec 20, 2022 See Note 2 F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The Reporting Person is the managing member of SR One Capital Management, LLC ("SR One Capital Management"), which is the sole general partner of SR One Capital Partners I, LP ("SR One Partners I"). SR One Partners I is the sole general partner of SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or otherwise of such portion of the SR One Fund I Aggregator securities in which the Reporting Person has no pecuniary interest, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purposes.
F3 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.25 to $8.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.86 to $8.45 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.